SPRY · PHARMACEUTICAL PREPARATIONS · 8-K · Item 2.02 · Aug 13, 2026

neffy is growing—but ARS just admitted the launch was overspending

In linenew

$33.7M revenue vs ~$32.0M consensus; EPS -$0.63 vs ~-$0.50 consensus

Next Interim CSU Phase 2b data, Q1 2027

ARS Pharmaceuticals, Inc. (SPRY) — AllSight decodes this SEC 8-K in plain English, versus what the market expected.

The next major valuation test is clinical, not another routine quarter. Interim Phase 2b data for ARS-2 in chronic spontaneous urticaria is now expected in Q1 2027. The program could expand the platform into an area with no FDA-approved on-demand treatment for acute flares, but the filing provides no efficacy result yet; for now, it is an option value rather than delivered evidence. (Expanding the Intranasal Epinephrine Platform)

Read the original 8-K on SEC EDGAR ↗

Open live on AllSight — the whole market, decoded →

AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.